Replies to post #133542 on Biotech Values

[mcbio]

The HER2 space is getting quite crowded, so that could make finding a partner difficult.

Definitely getting crowded but that small Phase 1 trial showed activity in patients that I believe had all failed Herceptin and 81% failed Tykerb so that has to be encouraging I would think.

The phase I study is too small to characterize the true safety profile of the compound (something like cardiac adverse events would probably only be evident in a larger trial).

Yep, I agree with that.

Do you know if it is a reversible or irreversible inhibitor of HER2?

It's reversible per ARRY's Web site (http://www.arraybiopharma.com/ProductPipeline/Cancer/HER2.asp ). Which is preferable and why?